A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Purpose: To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas. Methods: This was a single-institution, phase I, dose-escalation study of PF-04929113 administered twice weekly. Endpoints included determination of dose-limiting toxicities (DLT), MTD, the safety profile of PF-04929113, pharmacodynamic assessment of PF-04929113 on Hsp70 induction, pharmacokinetic analysis of PF-04928473 (SNX-2112) and its prodrug PF-04929113, and assessment of response. Results: Thirty-three patients with advanced malignancies were treated. Dose escalation was continued up to 177 mg/m2 administered orally twice a week. One DLT (nonseptic arthritis) was noted. No grade 4 drug-related adverse events were seen; grade 3 adverse events included diarrhea (9%), nonseptic arthritis (3%), aspartate aminotransferase elevation (3%), and thrombocytopenia (3%). No objective responses were seen in 32 evaluable patients. Fifteen patients (47%) had stable disease; 17 patients (53%) had progressive disease. Pharmacokinetic data revealed rapid absorption, hepatic, and extrahepatic clearance, extensive tissue binding, and almost linear pharmacokinetics of the active drug PF-04928473. Pharmacodynamic studies confirmed inhibition of Hsp90 and a linear correlation between pharmacokinetic parameters and Hsp70 induction. Conclusions: PF-04929113 administered orally twice a week is well tolerated and inhibits its intended target Hsp90. No objective responses were seen, but long-lasting stabilizations were obtained. Although no clinically significant drug-related ocular toxicity was seen in this study, the development of PF-04929113 has been discontinued because of ocular toxicity seen in animal models and in a separate phase I study. Clin Cancer Res; 17(21); 6831–9. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
Cited by
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
“Hsp90 inhibitor SNX-5422 developed by Pfizer terminated clinical phase 1 trial in 2011 due to ocular toxicity.(116) Therefore, researchers believe that targeting Hsp90 and its molecular chaperones is a new direction for the cancer treatment study.”
BackgroundHeat Shock Proteins and Cancer
Wu, J., Liu, T., Rios, Z., Mei, Q., Lin, X., & Cao, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.11.009 · Cited by 696
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
Jhaveri, K., Taldone, T., Modi, S., & Chiosis, G. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.10.008 · Cited by 456
Inhibition of HSP90 molecular chaperones: moving into the clinic
Garcia-Carbonero, R., Carnero, A., & Paz-Ares, L. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70169-4 · Cited by 351
Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update
Ciocca, D. R., Arrigo, A. P., & Calderwood, S. K. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0918-z · Cited by 265
Metadata
- Authors
- Rajan, A., Kelly, R. J., Trepel, J. B., Kim, Y. S., Alarcon, S. V., Kummar, S., Gutierrez, M., Crandon, S., Zein, W. M., Jain, L., Mannargudi, B., Figg, W. D., Houk, B. E., Shnaidman, M., Brega, N., & Giaccone, G.
- Venue
- Clinical Cancer Research
- Published
- 2011-10-31
- Volume
- 17
- Issue
- 21
- Pages
- 6831-6839
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2085961273
- Cited by
- 143
- References
- 1
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-0821
- The paper
- Rajan, A., Kelly, R. J., Trepel, J. B., Kim, Y. S., Alarcon, S. V., Kummar, S., Gutierrez, M., Crandon, S., Zein, W. M., Jain, L., Mannargudi, B., Figg, W. D., Houk, B. E., Shnaidman, M., Brega, N., & Giaccone, G. (2011). A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-0821
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.